Chandra P Belani
Affiliation: Pennsylvania State University
Belani C. The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. Cancer Invest. 2010;28:413-23 pubmed publisher
..Irreversible epidermal growth factor receptor tyrosine kinase inhibitors are an emerging class of agents that may have the potential to overcome and prevent the emergence of such mutation-related resistance. ..
Belani C, Ramalingam S, Perry M, LaRocca R, Rinaldi D, Gable P, et al
. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:468-73 pubmed publisher
..All efficacy parameters were similar between the two treatment arms. The favorable nonhematologic toxicity profile of arm 1 makes this an alternative treatment option for patients with advanced NSCLC. ..
Belani C, Brodowicz T, Ciuleanu T, Krzakowski M, Yang S, Franke F, et al
. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol. 2012;13:292-9 pubmed publisher
..Eli Lilly. ..